Sort by
Search results
BIOPHEN Heparin 6
Measuring the heparin concentration in patients’ plasma for monitoring the therapy and adjusting drug dosage.
BIOPHEN Heparin 3
Measuring the heparin concentration in patients’ plasma for monitoring the therapy and adjusting drug dosage.
BIOPHEN DiXaI (Direct Xa Inhibitors)
Measurement of rivaroxaban and other factor Xa inhibitors in citrated plasma or other biological fluids. Note: BIOPHEN Heparin LRT and BIOPHEN Heparin (3 or 6) can also be used for testing direct factor Xa inhibitors (DiXaIs), such as rivaroxaban, apixaban or edoxaban. Adjusted protocols are available on demand.
BIOPHEN Antithrombin 5 (anti-Xa)
Diagnosis of congenital or acquired antithrombin deficiencies. Measurement of AT activity in biological milieu or purified fractions.
BIOPHEN Antithrombin 2.5 (Anti-Xa)
Diagnosis of congenital or acquired antithrombin deficiencies. Measurement of AT activity in biological milieu or purified fractions.
BIOPHEN α2-Antiplasmin (Plasmin Inhibitor) LRT
Assay proposed for the measurement of plasmin inhibitor (α2-antiplasmin) activity in research applications.
BIOPHEN Factor V-L Control Plasma
Quality control plasma for the qualitative or quantitative assay of FV-Leiden (resistant to APC), with clotting assays (e.g. HEMOCLOT Factor V-L, HEMOCLOT Quanti. VL).
BIOPHEN Factor V-L Plasma Calibrator
Calibration of HEMOCLOT Quanti. VL kit (CK065K).
FIBRIPHEN 5
Measurement of fibrinogen in plasma. Detection of low fibrinogen concentrations. Detection of elevated fibrinogen concentrations (> 4g/L): In clinical situations associated with inflammation Risk factor for cardiovascular disease and thrombosis Hypofibrinogenemia, mainly associated with severe liver disease, and excessive consumption of fibrinogen (DIC, hyperfibrinolysis). Numerous variants of fibrinogen described, associated to asymptomatic cases, or to cases with bleeding and/or thrombosis.
FIBRIPHEN 2
Measurement of fibrinogen in plasma. Detection of low fibrinogen concentrations. Detection of elevated fibrinogen concentrations (> 4g/L): In clinical situations associated with inflammation Risk factor for cardiovascular disease and thrombosis Hypofibrinogenemia, mainly associated with severe liver disease, and excessive consumption of fibrinogen (DIC, hyperfibrinolysis). Numerous variants of fibrinogen described, associated to asymptomatic cases, or to cases with bleeding and/or thrombosis.